Cilostazol improves the response to ischemia in diabetic mice by a mechanism dependent on PPARγ

Molecular and Cellular Endocrinology

Volumn 381, Issue 1-2, 2013, Pages 80-87

  Biscetti, Federico ^a,b   Pecorini, Giovanni ^a   Arena, Vincenzo ^b   Stigliano, Egidio ^b   Angelini, Flavia ^a   Ghirlanda, Giovanni ^a   Ferraccioli, Gianfranco ^b   Flex, Andrea ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Angiogenesis; Cilostazol; Diabetes; Peroxisome proliferator activated receptor; PPAR

Indexed keywords

CILOSTAZOL; GLUCOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLLATERAL CIRCULATION; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG RECEPTOR BINDING; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; IN VIVO STUDY; LIMB BLOOD FLOW; LIMB ISCHEMIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; STREPTOZOCIN DIABETES; TREATMENT OUTCOME; UPREGULATION;

ANGIOGENESIS; CILOSTAZOL; DIABETES; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; PPARΓ;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; HINDLIMB; ISCHEMIA; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PHYSIOLOGIC; PPAR GAMMA; REGIONAL BLOOD FLOW; TETRAZOLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84882784153     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.07.011     Document Type: Article

References (31)

1. Duh E., Aiello L.P. Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes 1999, 48:1899-1906.
2. Leibson C.L., Ransom J.E., Olson W., Zimmerman B.R., O'Fallon W.M., Palumbo P.J. Peripheral arterial disease, diabetes, and mortality. Diabetes Care 2004, 27:2843-2849.
3. Hiatt W.R. Medical treatment of peripheral arterial disease and claudication. N. Engl. J. Med. 2001, 344:1608-1621.
4. American Diabetes Association, 2003. Peripheral arterial disease in people with diabetes. Diabetes Care 26, 3333-3341.
5. Dawson D.L., Cutler B.S., Hiatt W.R., Hobson R.W., Martin J.D., Bortey E.B., Forbes W.P., Strandness D.E. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am. J. Med. 2000, 109:523-530.
6. Ikeda Y., Kikuchi M., Murakami H., Satoh K., Murata M., Watanabe K., Ando Y. Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study. Arzneimittelforschung 1987, 37:563-566.
7. Kamiya T., Sakaguchi S. Hemodynamic effects of the antithrombotic drug cilostazol in chronic arterial occlusion in the extremities. Arzneimittelforschung 1985, 35:1201-1203.
8. Hashimoto A., Miyakoda G., Hirose Y., Mori T. Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis 2006, 189:350-357.
9. Elam M.B., Heckman J., Crouse J.R., Hunninghake D.B., Herd J.A., Davidson M., Gordon I.L., Bortey E.B., Forbes W.P. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler. Thromb. Vasc. Biol. 1998, 18:1942-1947.
10. Biscetti F., Pecorini G., Straface G., Arena V., Stigliano E., Rutella S., Locatelli F., Angelini F., Ghirlanda G., Flex A. Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism. Int. J. Cardiol. 2013, 167:910-916.
11. Biscetti F., Straface G., Pitocco D., Zaccardi F., Ghirlanda G., Flex A. Peroxisome proliferator-activated receptors and angiogenesis. Nutr. Metab. Cardiovasc. Dis. 2009, 19:751-759.
12. Rivard A., Silver M., Chen D., Kearney M., Magner M., Annex B., Peters K., Isner J.M. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am. J. Pathol. 1999, 154:355-363.
13. Biscetti F., Gaetani E., Flex A., Aprahamian T., Hopkins T., Straface G., Pecorini G., Stigliano E., Smith R.C., Angelini F., Castellot J.J., Pola R. Selective activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism. Diabetes 2008, 57:1394-1404.
14. Park S.Y., Shin H.K., Lee J.H., Kim C.D., Lee W.S., Rhim B.Y., Hong K.W. Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in a db/db mouse model of type 2 diabetes via activation of peroxisome proliferator-activated receptor gamma transcription. J. Pharmacol. Exp. Ther. 2009, 329:571-579.
15. Biscetti F., Straface G., De Cristofaro R., Lancellotti S., Rizzo P., Arena V., Stigliano E., Pecorini G., Egashira K., De Angelis G., Ghirlanda G., Flex A. High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism. Diabetes 2010, 59:1496-1505.
16. Biscetti F., Straface G., Arena V., Stigliano E., Pecorini G., Rizzo P., De Angelis G., Iuliano L., Ghirlanda G., Flex A. Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPARgamma stimulation. Cardiovasc. Diabetologia 2009, 8:49.
17. Collino M., Patel N.S., Lawrence K.M., Collin M., Latchman D.S., Yaqoob M.M., Thiemermann C. The selective PPARgamma antagonist GW9662 reverses the protection of LPS in a model of renal ischemia-reperfusion. Kidney Int. 2005, 68:529-536.
18. Airoldi I., Di Carlo E., Cocco C., Taverniti G., D'Antuono T., Ognio E., Watanabe M., Ribatti D., Pistoia V. Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. Proc. Natl. Acad. Sci. USA 2007, 104:3996-4001.
19. Wang F., Gao L., Gong B., Hu J., Li M., Guan Q., Zhao J. Tissue-specific expression of PPAR mRNAs in diabetic rats and divergent effects of cilostazol. Can. J. Physiol. Pharmacol. 2008, 86:465-471.
20. Kantharidis P., Wang B., Carew R.M., Lan H.Y. Diabetes complications: the microRNA perspective. Diabetes 2011, 60:1832-1837.
21. Kota B.P., Huang T.H., Roufogalis B.D. An overview on biological mechanisms of PPARs. Pharmacol. Res. 2005, 51:85-94.
22. Fajas L., Auboeuf D., Raspe E., Schoonjans K., Lefebvre A.M., Saladin R., Najib J., Laville M., Fruchart J.C., Deeb S., Vidal-Puig A., Flier J., Briggs M.R., Staels B., Vidal H., Auwerx J. The organization, promoter analysis, and expression of the human PPARgamma gene. J. Biol. Chem. 1997, 272:18779-18789.
23. Hori, A., Shibata, R., Morisaki, K., Murohara, T., Komori, K., 2012. Cilostazol stimulates revascularisation in response to ischaemia via an eNOS-dependent mechanism. Eur. J. Vasc. Endovasc. Surg. 43, 62-65.
24. Biscetti F., Pitocco D., Straface G., Zaccardi F., de Cristofaro R., Rizzo P., Lancellotti S., Arena V., Stigliano E., Musella T., Ghirlanda G., Flex A. Glycaemic variability affects ischaemia-induced angiogenesis in diabetic mice. Clin. Sci. (London) 2011, 121:555-564.
25. Lee W.C., Chen H.C., Wang C.Y., Lin P.Y., Ou T.T., Chen C.C., Wen M.C., Wang J., Lee H.J. Cilostazol ameliorates nephropathy in type 1 diabetic rats involving improvement in oxidative stress and regulation of TGF-Beta and NF-kappaB. Biosci. Biotechnol. Biochem. 2010, 74:1355-1361.
26. Shin H.K., Kim Y.K., Kim K.Y., Lee J.H., Hong K.W. Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol. Circulation 2004, 109:1022-1028.
27. Lee J.H., Oh G.T., Park S.Y., Choi J.H., Park J.G., Kim C.D., Lee W.S., Rhim B.Y., Shin Y.W., Hong K.W. Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol. J. Pharmacol. Exp. Ther. 2005, 313:502-509.
28. Hueb W., Gersh B.J., Costa F., Lopes N., Soares P.R., Dutra P., Jatene F., Pereira A.C., Gois A.F., Oliveira S.A., Ramires J.A. Impact of diabetes on five-year outcomes of patients with multivessel coronary artery disease. Ann. Thorac. Surg. 2007, 83:93-99.
29. Rendell M., Cariski A.T., Hittel N., Zhang P. Cilostazol treatment of claudication in diabetic patients. Curr. Med. Res. Opin. 2002, 18:479-487.
30. Liang C., Ren Y., Tan H., He Z., Jiang Q., Wu J., Zhen Y., Fan M., Wu Z. Rosiglitazone via upregulation of Akt/eNOS pathways attenuates dysfunction of endothelial progenitor cells, induced by advanced glycation end products. Br. J. Pharmacol. 2009, 158:1865-1873.
31. Werner C., Kamani C.H., Gensch C., Bohm M., Laufs U. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance. Diabetes 2007, 56:2609-2615.